Desmopressin (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro

Platelets

Volumn 25, Issue 1, 2014, Pages 8-15

  Calmer, Simone ^a   Ferkau, Annika ^a   Larmann, Jan ^a   Johanning, Kai ^a   Czaja, Eliana ^a   Hagl, Christian ^a,b   Echtermeyer, Frank ^a   Goudeva, Lilia ^a   Heuft, Hans Gert ^a   Theilmeier, Gregor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

DDAVP; Endothelium; Flow chamber; Matrix; Platelet adhesion

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; COLLAGEN; DESMOPRESSIN; FRESH FROZEN PLASMA; HEPARIN; PHENPROCOUMON; PROTAMINE SULFATE; VON WILLEBRAND FACTOR;

ANAPHYLAXIS; AORTA VALVE REPLACEMENT; ARTICLE; BIOCHIP; BLEEDING; BLOOD CLOTTING TIME; BLOOD GAS ANALYSIS; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ELISA KIT; ENDOTHELIUM CELL; EX VIVO STUDY; FLUORESCENCE MICROSCOPE; HEPARINIZATION; HUMAN; IN VITRO STUDY; LIMIT OF DETECTION; PRIORITY JOURNAL; SHEAR FLOW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; WEIBEL PALADE BODY; WESTERN BLOTTING;

BLOOD PLATELETS; CELL COMMUNICATION; CELLS, CULTURED; COLLAGEN; DEAMINO ARGININE VASOPRESSIN; ENDOTHELIAL CELLS; HUMANS; PLATELET ACTIVATION; PLATELET ADHESIVENESS; VON WILLEBRAND FACTOR;

EID: 84892711300     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.767442     Document Type: Article

References (43)

1. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, Wagner DD. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000;191: 1413-1422.
2. Turitto VT, Baumgartner HR. Platelet interaction with subendothelium in a perfusion system: Physical role of red blood cells. Microvasc Res 1975;9: 335-344.
3. Jones GT, van Rij A. In situ von Willebrand factor staining in human arteries and veins. Thromb Res 2000;97: 369-374.
4. De Meyer GR, Hoylaerts MF, Kockx MM, Yamamoto H, Herman AG, Bult H. Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler Thromb Vasc Biol 1999;19: 2524-2534.
5. Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, Vermylen J, Hoylaerts MF. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002;99: 4486-4493.
6. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003;1: 682-689.
7. Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000;106: 107-116.
8. Schulman S. DDAVP - the multipotent drug in patients with coagulopathies. Transfus Med Rev 1991;5: 132-144.
9. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997;90: 2515-2521.
10. Datta YH, Ewenstein BM. Regulated secretion in endothelial cells: Biology and clinical implications. Thromb Haemost 2001;86: 1148-1155.
11. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: An interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995;92: 7450-7454.
12. Hartmann S, Reinhart W. Fatal complication of desmopressin. Lancet 1995;345: 1302-1303.
13. Theilmeier G, Lenaerts T, Remacle C, Collen D, Vermylen J, Hoylaerts MF. Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. Blood 1999;94: 2725-2734.
14. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996;88: 1525-1541.
15. Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost 2003;1: 821-828.
16. Tomasiak M, Stelmach H, Rusak T, Ciborowski M, Radziwon P. Vasopressin acts on platelets to generate procoagulant activity. Blood Coagul Fibrinolysis 2008;19: 615-624.
17. Vanderwel M, Lum DS, Haslam RJ. Vasopressin inhibits the adenylate cyclase activity of human platelet particulate fraction through V1-receptors. FEBS Lett 1983;164: 340-344.
18. Thibonnier M, Roberts JM. Characterization of human platelet vasopressin receptors. J Clin Invest 1985;76: 1857-1864.
19. Ghosh S, Rao AK. Lack of effect of 1-desamino-8-d-arginine vasopressin on direct adhesion of platelets to collagen. Thromb Res 1993;70: 417-422.
20. Yang X, Disa J, Rao AK. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. Thromb Res 1990;59: 809-818.
21. Sloand EM, Alyono D, Klein HG, Chang P, Yu M, Lightfoot FG, Kessler C. 1-Deamino-8-d-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994;46: 199-207.
22. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica 1999;84: 891-896.
23. Nieswandt B, Watson SP. Platelet-collagen interaction: Is GPVI the central receptor? Blood 2003;102: 449-461.
24. Lethagen S. Desmopressin in mild hemophilia A: Indications, limitations, efficacy, and safety. Semin Thromb Hemost 2003;29: 101-116.
25. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino- 8-d-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977;1: 869-872.
26. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975;30: 81-93.
27. Takeuchi K, Inaba M, Miyashima S, Ogawa R, Ikehara S. A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice. Blood 1998;91: 4616-4623.
28. Federici AB, de Groot PG, Moia M, Ijsseldijk MJ, Sixma JJ, Mannucci PM. Type I von Willebrand disease, subtype 'platelet low': Decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. Br J Haematol 1993;83: 88-93.
29. Jennings LK. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009;102: 248-257.
30. Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008;99: 480-486.
31. Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P. Desmopressin induces endothelial Pselectin expression and leukocyte rolling in postcapillary venules. Blood 1995;86: 2760-2766.
32. Takeuchi M, Nagura H, Kaneda T. DDAVP and epinephrineinduced changes in the localization of von Willebrand factor antigen in endothelial cells of human oral mucosa. Blood 1988;72: 850-854.
33. Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000;96: 3322-3328.
34. Tomokiyo K, Kamikubo Y, Hanada T, Araki T, Nakatomi Y, Ogata Y, Jung SM, Nakagaki T, Moroi M. von Willebrand factor accelerates platelet adhesion and thrombus formation on a collagen surface in platelet-reduced blood under flow conditions. Blood 2005;105: 1078-1084.
35. Solomon C, Budde U, Schneppenheim S, Czaja E, Hagl C, Schoechl H, von Depka M, Rahe-Meyer N. Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery. Br J Anaesth 2011;106: 494-500.
36. Hanke AA, Dellweg C, Kienbaum P, Weber CF, Gorlinger K, Rahe-Meyer N. Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: An in vitro study using multiple electrode aggregometry. Anaesthesia 2010;65: 688-691.
37. Carless PA, Henry DA, Moxey AJ, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004;1:CD001884.
38. Gurusamy KS, Li J, Sharma D, Davidson BR. Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev 2009;4:CD008085.
39. Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 2012; 18: 25-33.
40. Prohaska W, Zittermann A, Luth JU, Inoue K, Koster-Eiserfunke W, Baller D, Korfer R, Kleesiek K. Prevalent platelet dysfunction in patients with aortic valve disease. J Heart Valve Dis 2008;17: 542-547.
41. Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003;349: 343-349.
42. Yoshida K, Tobe S, Kawata M. Acquired von Willebrand disease type IIA in patients with aortic valve stenosis. Ann Thorac Surg 2006;81: 1114-1116.
43. Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jambor C. A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery. Anesth Analg 2010;110: 702-707.